Insys Therapeutics
1333 S Spectrum Boulevard
Suite 100
Chandler
Arizona
85286
United States
Tel: 602-910-2617
Fax: 602-910-2627
Email: info@insysrx.com
180 articles about Insys Therapeutics
-
INSYS Therapeutics to Present at the 2013 JMP Securities Healthcare Conference
7/3/2013
-
INSYS Therapeutics Completes $37 Million IPO to Back Medical Marijuana Drug
5/21/2013
-
INSYS Therapeutics Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option
5/7/2013
-
INSYS Therapeutics Announces Pricing of IPO
5/2/2013
-
INSYS Therapeutics Announces the Availability of SUBSYS(TM) (Fentanyl Sublingual Spray) for Breakthrough Cancer Pain
3/26/2012
-
INSYS Therapeutics Announces FDA Approval of SUBSYS(R) Fentanyl Sublingual Spray
1/6/2012
-
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
12/5/2011
-
INSYS Therapeutics Announces Commercial Team Additions
11/2/2011
-
INSYS Therapeutics Announces NDA PDUFA Date for Fentanyl SL Spray
5/23/2011
-
INSYS Therapeutics Announces NDA PDUFA Date for Fentanyl SL Spray
5/20/2011
-
INSYS Therapeutics Announces NDA Acceptance of its Fentanyl SL Spray
5/12/2011
-
INSYS Therapeutics Announces Submission of NDA for Fentanyl SL Spray
3/8/2011
-
INSYS Therapeutics Announces Conference Call and Corporate Update
2/14/2011
-
Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm as Chief Development Officer
1/7/2011
-
Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm As Chief Development Officer
1/6/2011
-
NeoPharm Completes Merger with INSYS Therapeutics
11/10/2010
-
NeoPharm Announces Merger with INSYS Therapeutics
11/1/2010
-
INSYS Therapeutics Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
3/9/2010
-
INSYS Therapeutics Announces Completion of Efficacy Trial for Fentanyl Sublingual Spray
1/26/2010
-
INSYS Therapeutics Files to Withdraw IPO Plans
9/9/2008